Summary.-Plasma CEA values and serum y glutamyl transpeptidase activities have been compared in control subjects and 109 patients with colorectal carcinoma and 35 with non-malignant hepatic disease. CEA values alone differentiate hepatic metastases from non-malignant hepatic disease with a high degree of certainty. While CEA may be elevated with metastases, irrespective of site, yGT is elevated mainly in association with hepatic metastases. The combination of CEA and yGT is helpful in identifying hepatic metastases and in their differentiation from local recurrences or metastases to other sites.
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THERE HAVE BEEN several publications describing initial experiences in the use of plasma carcinoembryonic antigen (CEA) levels in the detection of gastrointestinal cancer in clinical practice (Gold and Freedman, 1965; Lo Gerfo et al., 1972; Zamcheck et al., 1972) . There is, however, growing evidence that plasma CEA may be increased in a wide spectrum of malignant and non-malignant disease (Laurence et al., 1972; Lo Gerfo, Krypey and Hansen, 1971) ; this has been the subject of a recent review (Laurence and Munro Neville, 1972 Aronsen, Nosslin and Pihl (1970) suggested that a multiparametric discriminant analysis based on serum y glutamyl transpeptidase (yGT), alkaline phosphatase, alanine aminotransferase and bilirubin can achieve a 9300 correct diagnosis of liver involvement by cancer. Other authors suggest that yGT alone is of similar value and is indeed the predominant factor in this analysis (Delarue et al., 1973; Huguet and Azzopardi, 1970) . However, Baden et al. (1971) were not convinced that yGT alone, or the combination of yGT and alkaline phosphatase, was reliable in the detection of hepatic metastases.
The use of combinations of CEA and other tests has not hitherto been reported. In this paper we describe the use of combinations of plasma CEA and serum yGT for the detection of metastatic colorectal cancer and for distinguishing the sites of the metastases. (Rollason, Pincherle and Robinson, 1972 ; Rosalki and Rau, 1972) and possibly CEA (Delwiche, Zamcheck and Harcon, 1973 I'°°°r-hepatic disease are shown in Fig. 1 . The normal value for CEA, as measured by our method, is 129 + 40ng/ml. Thereis considerable overlap between the disease groups. Figure 2 shows CEA plotted against yGT in patients presenting with primary colorectal cancers. We have arbitrarily adopted a discriminant level of CEA of 100 ng/ml and a discriminant level of yGT of 45 i.u./l. NormalyGT values are 139 ± 77 i.u./l. Using these discriminants, it can be seen that 37 out of 43 tumours without evidence of spread outside the bowel and its local lymph nodes or distant metastasis fall within the area bounded by the discriminants.
When hepatic metastases or local extension outside the bowel involving the peritoneum or pelvis were present, 14 out of 17 tumours had values on or outside the area bounded by the discriminants.
In Fig. 3 fortunately these were rarely seen in the group under study.
There would appear to be two advantages offered by using this combination of tests. First, it may be helpful when the clinician is faced with a patient with hepatomegaly after a long disease-free interval following the excision of a colonic or rectal cancer. The yGT indicates that the liver is diseased and the CEA value appears to discriminate between hepatomegaly due to metastatic cancer and benign hepatic disease with a high degree of certainty. Secondly, when used frequently during the surveillance of patients after excision of colorectal cancer, changes of levels of CEA and yGT may prove to be a very early indication that there are metastases in the liver. Long-term studies, the preliminary results of which indicate that these tests may be abnormal for 3-9 months before hepatic metastases are confirmed clinically, are now in progress. At present, the response of advanced metastatic colorectal cancer to chemotherapy is frequently disappointing (Moeitel, 1973) but these tests might provide an improvement in the outlook for such patients by allowing treatment to be given at an earlier stage.
Although the simple combination of these 2 tests provides good discrimination between the various stages of disease in patients with colorectal cancer, not all patients are classified correctly. It seems likely that the use of additional, carefully selected, parameters will improve discrimination further and will be of assistance both in early diagnosis and in monitoring the effects of treatment.
